A synopsis of the findings presented at EURETINA 2021 for ophthalmologists and retina specialists.
Gene-independent therapeutic strategies for retinal degeneration include optogenetic therapy
José-Alain Sahel, MD, explains that optogenetics involves the use of artificial photoreceptors from specific retinal cells to restore vision by transferring a gene that encodes for a light-sensitive protein that causes neuronal cells to respond to light stimulation.
Analyzing classifications of macula dystrophies
Carel B. Hoyng, MD, discusses his presentation regarding macula dystrophies, including Stargardt disease, Best disease, X-linked retinoschisis, and the peripherin-2 (PRPH2) gene.
LIGHTSITE II: Photobiomodulation a novel therapy for dry AMD
Professor Ben Burton detailed how dry AMD patients treated with photobiomodulation therapy have seen improvements in best-corrected visual acuity 9 months after treatment.
Brolucizumab injection offers improved vision in neovascular age-related macular degeneration
Cristina Cristian, MD, noted that an injection of brolucizumab treatment in patients with neovascular age-related macular degeneration led to a median improvement in visual acuity (VA) of 10.5 letters and the drug was well-tolerated.
Study targets the burden of geographic atrophy
Daniel Jones, PhD, discussed GA and emphasized the need for additional study to gain a better understanding of the burden experienced by patients.
Exploring new biological treatments in posterior uveitis
Quan Dong Nguyen, MD, MSc, FARVO, FASRS, speaks on the highlights of his presentation regarding new biological treatments of posterior uveitis.
Study: Better understanding is key to beating diabetes
Tunde Peto, MD, PhD, pointed out that while complications associated with diabetes develop over a long period, ophthalmologists today have an excellent understanding of diabetes-related eye changes.
Comparing suitable naïve versus pre-treated DME patients
Javier Zarranz-Ventura MD, PhD, FEBO, discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pre-treated DME patients, and what it means for future research.
Should anti-VEGF agents be used to treat patients with NPDR?
Jennifer Sun, MD, MPH, explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).
Creating the best care environment for patients with diabetic eye disease
Tunde Peto, MD, PhD, discusses her presentation on providing the best virtual care for patients with diabetic eye disease at EURETINA 2021.
AI: Capturing more information from OCT in neovascular AMD
Anat Loewenstein, MD, MHA, discussed how artificial intelligence can optimize optical coherence tomography.
Managing retinal folds, role of anterior vitreous in retinal detachments
Grazia Pertile, MD, discusses the highlights of her presentations on the management of retinal folds after retinal detachment and the role of the anterior vitreous as a cause of recurrent retinal detachment.
Study targets intravitreal injections for AMD and PCR risks
Marta Belmonte-Grau, MD, discussed the potential risk for posterior capsular rupture during cataract surgery.
Facing the challenges of treating peripheral hemorrhagic polypoidal choroidal vasculopathy
Treating the disease can be a challenge, and at the EURETINA 2021 Virtual Congress, Chekitaan Singh, MD, discussed a case study detailing the care of a patient who had already lost vision in one eye from a similar issue.
Discussing worldwide pathological myopia
Ramin Tadayoni, MD, PhD, discusses the myopia panel at the EURETINA 2021 virtual meeting.